More Than MOPP for Advanced Hodgkin's Disease?

Publisher Website
Google Scholar
Abstract
Hodgkin's disease is a relatively uncommon malignant disorder. It occurs in only 7000 Americans annually, but it has attracted special attention because it is the most common neoplasm in young adults (ages 15 to 29).1 Only 20 years ago, radiation therapy—technically inferior to that available today — was the sole effective form of treatment. Only 33 per cent of patients so treated survived for five years after diagnosis.2 The median survival period among patients with extensive nodal (Stage III) or extranodal (Stage IV) involvement, whether they were given single-agent chemotherapy or left untreated, was approximately 12 months.3 Advanced Hodgkin's disease . . .